Soligenix Inc. Common Stock (SNGX)
Stock · NASDAQ · Health Care
$0.35as of 10/16/2026
Price chart
Active signals
SNGX Signal Track Record
How signals performed across all stocks →What SNGX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 30 | -7.4% | 23% | September 29, 2026 |
| Bollinger Band Breakdown | 25 | -7.9% | 44% | April 28, 2026 |
| Bollinger Band Breakout | 18 | -18.1% | 11% | August 21, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -18.3% | 25% | September 22, 2025 |
| Any 20-session window (baseline) | -8.2% | 31% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cu…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 13
- Website
- www.soligenix.com/
Fundamentals
- 1-day range
- $0.346$0.3619
- Market cap
- $8.24M
- P/E (trailing)
- —
- P/E (forward)
- -1.41
- EPS (trailing)
- $-1.27
- Dividend yield
- —
- Beta
- 2.15
- Avg. volume
- 234.9K
- Dividend pay date
- October 7, 2016
How Soligenix Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 21, 2025 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Soligenix Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SNGXSoligenix Inc. Common Stock$0.35▼ 2.78%Market cap $8.24MP/E —$0.28$1.76
- TRAWTraws Pharma Inc. Common Stock$0.37▼ 7.50%Market cap $8.21MP/E —$0.391$3.23
- KAPAKairos Pharma Ltd. Common Stock$0.601▼ 10.43%Market cap $8.35MP/E —$0.7108$9.17
- ENSCEnsysce Biosciences Inc. Common Stock$0.518▼ 13.38%Market cap $8.06MP/E —$0.23$2.75
- XCURExicure Inc. Common Stock$1.12▲ 0.00%Market cap $8.60MP/E —$0.936$9.48
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
- LEXXLexaria Bioscience Corp. Common Stock$2.86▼ 4.35%Market cap $8.82MP/E —$2.43$21.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SNGX Soligenix Inc. Common Stock | $8.24M | — | $0.35 | ▼ 2.78% | $0.28$1.76 |
| TRAW Traws Pharma Inc. Common Stock | $8.21M | — | $0.37 | ▼ 7.50% | $0.391$3.23 |
| KAPA Kairos Pharma Ltd. Common Stock | $8.35M | — | $0.601 | ▼ 10.43% | $0.7108$9.17 |
| ENSC Ensysce Biosciences Inc. Common Stock | $8.06M | — | $0.518 | ▼ 13.38% | $0.23$2.75 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.12 | ▲ 0.00% | $0.936$9.48 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
| LEXX Lexaria Bioscience Corp. Common Stock | $8.82M | — | $2.86 | ▼ 4.35% | $2.43$21.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Parks Diane L. · September 17, 2026 · Grant78.9K
- Jerome B. Zeldis · September 17, 2026 · Grant78.9K
- RUBIN ROBERT J. · September 17, 2026 · Grant78.9K
- LAPOINTE ANTHONY GREGG · September 17, 2026 · Grant78.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 206.4K
- Total value held
- $243.5K
- Institutional holders
- 13
- Unknown120.3K
- Unknown58.4K
- Unknown20.8K
- Unknown3.6K
- Unknown2.3K
- Unknown402
- Unknown209
- Unknown209
- Unknown100
- Unknown19
See the full, filterable feed with live charts on the MarketWall dashboard.